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A B S T R A C T
Background: Mandibular repositioning devices (MRDs) are usually recommended as the ﬁrst therapy option
in patients with mild-to-moderate obstructive sleep apnoea (OSA). However, data on the long-term ef-
ﬁcacy of MRDs are limited, not only in OSA patients who are noncompliant with continuous positive airway
pressure (CPAP) but also in those with more severe OSA. The ORCADES study aimed to prospectively de-
termine the long-term eﬃcacy and tolerability of two custom-made Narval™ MRDs for obstructive sleep
apnoea–hypopnoea syndrome (OSAHS) patients. The interim 3- to 6-month data are reported.
Methods: Eligible patients had OSAHS and had refused or were noncompliant with prescribed CPAP.
Outcome measurements after gradual mandibular advancement titration included: apnoea–hypopnoea
index (AHI), oxygen saturation, sleepiness, symptoms, quality of life, side effects and compliance.
Results: A total of 369 patients were included. Overall, MRD treatment was successful (≥50% decrease
in AHI) in 76.2% of the participants; complete response (AHI <10/h) was achieved in 63.5%. Severe OSAHS
was effectively treated (AHI <15/h) in about 60% of the participants; 38% had complete symptom reso-
lution. Mandibular repositioning devices signiﬁcantly decreased subjective sleepiness, eliminated symptoms
and improved quality of life. They were well tolerated and compliance was excellent. Only 8% of the par-
ticipants stopped MRD treatment due to side effects.
Conclusion: Custom-made Narval™ MRDs are effective for mild to severe OSA in patients who refuse or
are noncompliant with CPAP. They are well tolerated and have excellent compliance.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The consensus deﬁnition of obstructive sleep apnoea–hypopnoea
syndrome (OSAHS) states that it is characterised by repetitive epi-
sodes of complete or partial upper airway obstruction during sleep
and is usually associated with snoring, intermittent hypoxaemia and
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sleep fragmentation [1]. Excessive daytime sleepiness is frequent and
increases the risk for vehicle crashes and occupational accidents [2].
Obstructive sleep apnoea–hypopnoea syndrome is associated with
signiﬁcant comorbidities and impaired quality of life (QOL) [3–5], and
is considered to be a major public health problem.
Treatment of behavioural consequences such as fatigue, sleepi-
ness, andmemory problems are important but not suﬃcient enough
to cure OSA. Upper airway surgery is only indicated in a small subset
of OSAHSpatientswhohave a speciﬁc aetiology [6]. Themostwidely
useddisease-speciﬁc therapies for treatingOSAHSsymptomsare: con-
tinuouspositive airwaypressure (CPAP) andmandibular repositioning
devices (MRDs). Continuouspositive airwaypressurehas been shown
to be a very effective treatment; it reduces sleepiness, road acci-
dents, cardiovascular risk and mortality [7–9]. However, good
adherence is needed to realise treatment beneﬁts [10] and 20–50%
of OSAHS patients are unable or unwilling to complywith CPAP [11].
Mandibular repositioning devices enlarge the upper airway during
sleep by holding the mandible in a forward position. They are ef-
ﬁcacious treatment alternatives for patients with mild-to-moderate
[12] or supine-position-dependent [13] OSAHS, or in those who are
noncompliant with CPAP. The effects of MRDs on sleep-disordered
breathing are usually inferior to CPAP, especially for apnoea–
hypopnoea index (AHI) reductions, but patient acceptability may
be better [14], with similar QOL and symptom effects.
Guidelines recommend MRDs as ﬁrst-line therapy for patients
with mild-to-moderate obstructive sleep apnoea (OSA) [15,16].
However, few studies have speciﬁcally assessed the long-term ef-
ﬁcacy of MRDs in OSA patients who are noncompliant with CPAP.
Discontinuation rates for MRD therapy in the literature are 14–
63% after four to ﬁve years [17–19].
These uncertainties about the long-term clinical beneﬁts of MRD
therapy resulted in the French Health Technology Assessment agency
(Haute Autorité de Santé) to request that each MRD manufacturer
provide additional clinical data on both the eﬃcacy and side effects
of their MRD devices over ﬁve years of treatment. The prospec-
tive, multicentre, observational ORCADES study determined the
eﬃcacy of two custom-made Narval™ MRDs in real-life conditions
over ﬁve years in a cohort of OSAHS patients who refused or were
noncompliant with CPAP. This paper presents the interim 3- to
6-month follow-up results.
2. Methods
2.1. Subjects
Patients with newly diagnosed OSAHS were recruited from 28
sleep centres across France. Inclusion criteria were: age ≥18 years;
OSAHS (AHI >30/h or AHI 5–30/h on polysomnography (PSG) or car-
diorespiratory polygraphy [PG]); excessive daytime sleepiness
assessed by the clinician and/or an Epworth Sleepiness Scale (ESS)
score >10; and refusal of or noncompliance with CPAP (pressure or
mask intolerance, compliance <3 hours/night). Patients were ex-
cluded if they had received previous MRD treatment or any of the
following characteristics: central apnoea index ≥5/h; AHI <30/h with
severe sleep comorbidities other than OSAHS; or coexisting psy-
chiatric disease. Patients with contraindications for MDR that had
been assessed by a dental specialist investigator were also ex-
cluded. All patients gave written informed consent to participate
in the study, which had ethics committee approval and was con-
ducted according to the Declaration of Helsinki principles
(ClinicalTrials.gov identiﬁer: NCT01326143).
2.2. Intervention
The Narval™ devices used in this study were bi-block MRDs that
were made with semi-rigid plastic materials (biocompatible
polymer) and customised using either a high-precision computer-
aided design (CAD)/computer-aided manufacturing (CAM)
(ResMed, Narval CC™) or non-CAD/CAM process (ResMed, Narval™)
(Fig. 1). Devices manufactured using non-CAD/CAM processes
are reserved for patients with tooth morphology that is unsuit-
able for CAD/CAM technology (eg, short teeth or removable appliance
leading to inadequate retention with CAD/CAM device). The
MRDs were gradually adjusted to provide mandibular advance-
ment over a 15-mm range. EachMRDwas ﬁtted by a dental specialist
with an initial advancement of 67 ± 18% of maximal jaw
protrusion. During titration, mandibular advancement was ad-
justed at the discretion of the dental sleep specialist until the best
beneﬁt–risk ratio between symptom resolution and tolerability was
achieved.
2.3. Endpoints
The primary endpoint used to assess the success of MRD therapy
was the proportion of patients with a ≥50% decrease in AHI from
baseline to follow-up (three to six months). This threshold is com-
monly used in clinical trials and was selected for this study because
of the evaluation of MRD as a second-line treatment in the absence
of another alternative therapy [16].
Secondary endpoints included: complete response to MRD treat-
ment (using AHI cut-off values of <5/h or <10/h), mean AHI decrease,
evolution of other respiratory criteria, OSAHS symptoms, QOL, com-
pliance and tolerability. Additional pre-planned subgroup analyses
were conducted in subgroups of patients according to AHI severi-
ty, previous CPAP therapy, diagnosis method (PG or PSG), and MRD
type.
Fig. 1. Examples of: (A) a non-computer-aided design/computer-aided manufac-
turing mandibular repositioning device and (B) a computer-aided design/computer-
aided manufacturing mandibular repositioning device.
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2.4. Assessments
Sleep and/or respiratory parameters were recorded during sleep
at baseline and the 3-month follow-up visit using the same PG or
PSG device used to diagnose OSAHS. If MRD therapy was subopti-
mal (AHI decrease of <50% and/or persistent symptoms), PSG/PG
was performed again at a 6-month follow-up visit after additional
mandibular advancement. The PSG/PG recordings were manually
scored according to the American Academy of Sleep Medicine
(AASM) guidelines [20]. Obstructive apnoea was deﬁned as a ≥10-s
cessation of airﬂow on the pressure nasal cannula, with or without
association with an oro-nasal thermal sensor. Hypopnoea was
deﬁned as a ≥50% reduction in airﬂow, or a <50% airﬂow reduc-
tion on the nasal pressure cannula accompanied by a ≥3% decrease
in arterial oxyhaemoglobin saturation (SpO2) recorded using ﬁnger
pulse oximetry or an arousal. The oxygen desaturation index (ODI)
describes the average number of desaturation episodes per hour,
with desaturation deﬁned as a ≥3% decrease in SpO2 from the average
value. Other recorded parameters were: the lowest value of SpO2
(nadir SpO2) and the total time that SpO2 was <90% (SpO2 <90%).
Objective data on snoring were obtained from PSG, including snoring
duration (as a percentage of total sleep time (TST)) and the number
of snoring events per hour of sleep.
At follow-up, investigators recorded self-reported clinical symp-
toms, including: snoring (daily snoring/loud snoring/bothersome
snoring); nocturnal polyuria; libido disorders; and nocturnal mouth
breathing. Sleep quality, state onwaking andmorning headachewere
recorded by the patient at baseline and follow-up on a visual an-
alogue scale (VAS) from 0 to 10. Subjective sleepiness, assessed using
the Epworth Sleepiness Scale (ESS score), QOL (Quebec Sleep Ques-
tionnaire [21]) and fatigue (Pichot scale [22]), was also determined
at baseline and the 3- to 6-month follow-up visits. Oﬃce blood pres-
sure (BP) was measured after 10 min of rest in the supine position
at baseline and during follow-up.
During the clinical examination at each follow-up visit, the treat-
ing physician subjectively determined, by patient self-report,
compliance with the MRD (number of hours used per night and
number of nights used per week). Comprehensive data on MRD-
related side effects were also collected at follow-up visits. The sleep
and dental sleep physicians determined the severity of side effects
and their impact on MRD treatment.
2.5. Statistical analysis
In this prospective study based on pre- and post-treatment evalu-
ations of the same subjects, the sample size was determined by the
accuracy required to estimate the primary endpoint with a conﬁ-
dence interval (CI) of 95%; a minimum sample size of n = 323 was
determined. It was also estimated that about 10% of participants
Fig. 2. Flow of participants through the study. CAD/CAM, computer-aided design/computer-aided manufacturing; MRD, mandibular repositioning device; PG, polygraphy;
PSG, polysomnography.
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would be lost to follow-up, resulting in a target sample size of 360
patients.
Quantitative changes from baseline to the 3- to 6-month follow-
up visits were presented as mean values, with standard deviation,
minimum, maximum, median and quartile values, and compared
using unpaired or paired Student’s t-test or the Wilcoxon–Mann–
Whitney nonparametric test according to normality of distribution
and group comparison. Qualitative changes were described using
frequency distribution and compared using Fisher’s exact test or Chi-
squared test. Comparisons between patient subgroups were assessed
using the Student’s t-test, ANOVA orWilcoxon–Mann–Whitney test.
Statistical analyses were performed using SAS version 9.
A logistic procedure with backward stepwise regression analy-
sis was used to determine the independent factors associated with
treatment success and complete response after selection of vari-
ables, with a p-value of <0.10 on univariate analysis. A p-value of
<0.05 was considered statistically signiﬁcant.
3. Results
3.1. Population
A total of 515 eligible patients were screened betweenMay 2011
and September 2013. One hundred and forty six were not re-
cruited into the study according to the following main reasons: 74
had maxillofacial contraindications to MRD therapy (temporoman-
dibular joint disorders, craniofacial dimorphism, poor dental or
periodontal status) and 72 declined to participate. Therefore, 369
eligible patients were included and treatedwith a CAD/CAM (n = 312)
or non-CAD/CAM (n = 57) MRD (Fig. 2). Overall, 50% of the partici-
pants had previously received CPAP (median duration 11 months;
median therapy pressure 11 cmH2O (Q1–Q3: 9–12 cmH2O)). Thirty
MRD-treated participants withdrew from the study before the
3-month follow-up, mainly because of side effects (n = 16). The PG/
PSG follow-up data were available for 337 participants. Eleven
participants without PG/PSG follow-up for either no valid reason
(n = 7) or early study withdrawal for subjective lack of eﬃcacy (n = 4)
were classiﬁed as treatment failures. Therefore, the primary end-
point was assessed in 348 participants. Baseline participant
demographic and clinical data are shown in Table 1.
3.2. MRD titration
In 84% of participants, at least one MRD titration visit was re-
quired (median 2, range 0–4); 25% required additional titration after
the ﬁrst PG/PSG control and were evaluated at the 6-month follow-
up visit. Mean mandibular advancement after the last titration was
7.3 ± 2.1 mm (85 ± 26% of maximal, Q1-Q3: 73–100%) irrespective
of the type of MRD.
3.3. Eﬃcacy
3.3.1. Primary endpoint
Mandibular repositioning device treatment success was achieved
in 76.2% of the participants (95% CI 71.4–80.3%).
3.3.2. Secondary endpoints
The complete response rates were 35.9% (AHI <5/h) and 63.5%
(AHI <10/h). An AHI <15/hwas achieved in 78% of participants during
MRD therapy. Correction of AHI was greater in mild-to-moderate
vs severe OSAHS (Fig. 3). However, more than half of all partici-
pants with severe OSAHS achieved an AHI of <15/h.
Treatment success was equivalent, irrespective of OSAHS sever-
ity at baseline (Fig. 3), previous CPAP therapy and diagnosis method.
However, the treatment success rate was higher in those using a
CAD/CAM vs non-CAD/CAMMRD (79.1% (95% CI 74.1–83.4%) vs 60.7%
(95% CI 47.6–72.4%); p = 0.0031). The complete response rate with
AHI <10/h was also higher in the CAD/CAM subgroup (66.2% (60.5–
71.5%) vs 49.1% (36.1–62.1%); p = 0.017).
3.3.2.1. Other respiratory criteria. Mandibular repositioning device
therapy had signiﬁcant beneﬁcial effects on AHI, apnoea index (AI),
hypopnoea index (HI), and ODI. Changes from baseline were sig-
niﬁcantly greater in participants with severe OSAHS at baseline vs
those with mild or moderate disease (Table 2). Mandibular repo-
sitioning device therapy had no signiﬁcant effect on mean SpO2, but
nadir values signiﬁcantly increased from baseline to follow-up, and
time with SpO2 <90% signiﬁcantly decreased during MRD therapy
(Table 2). Based on PSG assessment, the number of snoring events
decreased by 50% and the duration of snoring decreased by 75% com-
pared with baseline during MRD therapy (Fig. 4A).
3.3.2.2. PSG data. Baseline and follow-up PSG data were available
for 142 participants. There were no signiﬁcant changes from base-
line in total sleep time (TST) (417.1 ± 72.3 vs 411.9 ± 73.9 min), sleep
latency (−2.7 ± 39.0 min) and sleep stage durations (stage 1–2 non-
rapid eye movement (NREM): −2.8 ± 14.4% of TST; stage 3–4 NREM:
+1.7 ± 11.9% of TST; REM: +1.2 ± 8.4% of TST) during MRD therapy.
The number of arousals per hour decreased, irrespective of OSAHS
severity, from 24.2 ± 17.5 at baseline to 16.1 ± 12.1 at follow-up
(p < 0.0001). Although there was no overall change, participants with
severe OSAHS showed a signiﬁcant decrease in stage 1–2 NREM sleep
(median 6% decrease; p = 0.014) in favour of an increase in REM sleep
(median 3% increase; p = 0.023), without change in TST. Supine and
non-supine AHI were signiﬁcantly reduced from 37.0 ± 22.2 to
12.2 ± 16.0/h of TST (p < 0.001) and from 18.0 ± 17.5 to 6.3 ± 10.9 of
Table 1
Participant demographic, respiratory and clinical data at baseline.
Total (n = 369)
Male, n (%) 273 (74.0)
Age, years 52.6 ± 11.3
Body mass index, kg/m2 27.2 ± 4.3
Overweight, n (%) 171 (46.7)
Obese, n (%) 80 (21.9)
Waist circumference, cm 97.4 ± 12.4
Neck circumference, cm 39.7 ± 3.8
Systolic blood pressure, mmHg 127.2 ± 12.5
Diastolic blood pressure, mmHg 78.3 ± 10.3
AHI, /h 29.5 ± 15.2
Supine AHI, /h 37.0 ± 22.4
AI, /h 12.7 ± 12.9
HI, /h 16.8 ± 10.3
cAI, /h 0.5 ± 1.2
SpO2, % 93.7 ± 2.0
Minimum SpO2, % 81.7 ± 7.6
Median time SpO2 <90%, min 7
ODI, /h 21.7 ± 18.4
Dental status, n (%)
Good 301 (82.2)
Acceptable 65 (17.8)
Periodontal status, n (%)
Good 294 (80.3)
Acceptable 72 (19.7)
Dental mobility, n (%)
None 342 (93.4)
Low and limited 24 (6.6)
Angle malocclusion, n (%)
Type 1 236 (66.7)
Type 2 102 (28.8)
Type 3 16 (4.5)
Values are mean ± standard deviation or number of patients (%), unless otherwise
stated.
AHI, apnoea–hypopnoea index; AI, apnoea index; cAI, central apnoea index; HI,
hypopnoea index; MRD, mandibular repositioning device; ODI, oxygen desaturation
index; SpO2, oxygen saturation.
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TST (p < 0.001), respectively; TST in the supine (197.6 ± 109.5 vs
208.8 ± 115.4min) or non-supine (226.0 ± 121.1 vs 212.9 ± 116.0min)
position was unchanged.
3.3.2.3. Daytime sleepiness. The ESS score decreased from 11.2 ± 4.8
at baseline to 7.8 ± 4.3 during MRD therapy; p < 0.0001). Overall, 62%
of participants with excessive sleepiness at baseline had complete
symptom resolution.
3.3.2.4. Clinical symptoms. Most clinical symptoms signiﬁcantly im-
proved during MRD therapy. Data on reductions in objective and
subjective snoring are shown in Fig. 4A and B, respectively. Noc-
turnal polyuria and libido disorders resolved in 64% and 81% of
participants affected by these problems at baseline and there was
a signiﬁcant reduction in the percentage of those with moderate
or severe OSAHS who had nocturnal mouth breathing (p = 0.0001).
Improvements in polyuria were seen across disease severity sub-
groups (p < 0.0001), but libido disorders only improved in those with
severe OSAHS (p < 0.01). Visual analogue scale scores for sleep, state
onwaking, andmorning headache signiﬁcantly improved from base-
line to follow-up (p < 0.0001).
3.3.2.5. Quality of life. Signiﬁcant improvements from baseline (+24%)
were documented in all ﬁve domains of the Quebec Sleep Ques-
tionnaire duringMRD therapy (Fig. 5), irrespective of OSAHS severity.
The Pichot score signiﬁcantly decreased from 14.1 ± 7.8 at base-
line to 9.0 ± 7.2 at follow-up (p < 0.0001).
3.3.2.6. Blood pressure and body weight. There were no changes in
body weight, mean oﬃce systolic or diastolic BP, or heart rhythm
from baseline to 3-month follow-up.
3.3.3. Tolerability
Fifty per cent of participants reported side effects during MRD
therapy (Table 3). The most common events were temporoman-
dibular joint or dental pain, and feelings of dental occlusion change.
The majority of side effects were of mild severity and the investi-
gators classiﬁed only 14% as severe. Pain was usually transitory and
resolved within a median of 10min of MRD removal in the morning.
Twenty-eight participants (8%) prematurely discontinued MRD
therapy because of side effects, which were similar across OSAHS
severity subgroups, and there were no differences between the two
types of MRD.
3.3.4. Compliance
Mean subjective compliance was 6.7 ± 1.3 hours/night, 6.7 ± 0.9
nights/week. The majority of participants (96.1%) used the MRD for
≥4 h/night, ≥4 days/week, and 86% used the device every night. Com-
pliance results were similar regardless of OSAHS severity or MRD
type.
3.3.5. Factors predictive of MRD eﬃcacy
Univariate analysis identiﬁed a number of statistically signiﬁ-
cant factors at a threshold of 10% to predict a ≥50% decrease in AHI
from baseline (Table 4). In an adjusted multivariate analysis, ﬁve
factors remained as statistically signiﬁcant predictors of a ≥50% de-
crease in AHI: use of a CAD/CAM MRD (odds ratio (OR) 3.02, 95%
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Fig. 3. Mandibular repositioning device eﬃcacy by obstructive sleep apnoea–hypopnoea syndrome severity at 3- to 6-month follow-up. AHI, apnoea–hypopnoea index;
Success rate, percentage of patients with a ≥50% decrease in AHI from baseline to follow-up.
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CI 1.44–6.33; p = 0.0035); waist circumference (OR 0.97, 95% CI 0.94–
0.99; p = 0.0072); dental overbite (OR 1.22, 95% CI 1.03–1.45;
p = 0.022); maximal jaw protrusion (OR 1.18, 95% CI 1.03–1.35;
p = 0.015); and baseline AI (OR 0.97, 95% CI 0.95–0.99; p = 0.016).
There were also a number of signiﬁcant univariate predictors of
complete response (AHI <10/h) during MRD therapy (Table 4). On
adjusted multivariate regression analysis, four factors were signif-
icant independent predictors of complete response: use of CAD/
CAMMRD (OR 2.99, 95% CI 1.42–6.29; p = 0.0039); baseline AI (OR
0.89, 95% CI 0.87–0.92; p < 0.0001); maximal jaw protrusion (OR 1.21,
95% CI 1.07–1.37; p = 0.0018); and baseline HI (OR 0.93, 95% CI 0.90–
0.95; p < 0.0001). Age, body mass index, and supine AHI were not
identiﬁed as predictive factors of MRD eﬃcacy.
4. Discussion
This prospective observational study described the treatment of
369 patients with OSAHS and with an MRD. Although MRDs have
a place in the management of OSAHS, it is believed that, to date,
there are few comparative studies looking at the eﬃcacy and tol-
erability of different oral appliances [23]. Available data suggest that
custom-made and adjustable devices are more effective than pre-
fabricated, ﬁxed, thermoplastic appliances [24,25]. In the absence
of direct comparative trials, multiple factors can make comparing
data from different studies diﬃcult, including: heterogeneity in
OSAHS severity, variety in MRD type, and use of varying treat-
ment success deﬁnitions [26].
This study had a number of strengths. These included its
multicentre real-life design, the large sample (369 participants), ob-
jective titration with PSG/PG at the end of ﬁnal titration, re-
evaluation of suboptimal eﬃcacy after optimisation of mandibular
advancement, and amultidisciplinary approach involving sleep phy-
sicians and sleep dental specialists. Primary and eﬃcacy endpoints
were assessed in more than 90% of participants and the propor-
tion lost to follow-up was very low (<2%). In addition, the study
identiﬁed some predictive factors of eﬃcacy and showed that MRD
therapy can be successful in some patients with severe OSAHS and/
or obesity.
Participants were carefully selected, based on oral conditions as
recommended by current guidelines. However, the proportion of
screened patients who were not selected by a dental specialist for
MRD therapy (15%) was lower than expected. Other data show that
MRD contraindications could be present in up to 34% of patients,
mainly due to dental problems [27]. Furthermore, participants in
Table 2
Changes in respiratory parameters from baseline to follow-up based on severity of obstructive sleep apnoea–hypopnoea syndrome in participants treated with a mandibu-
lar repositioning device.
OSAHS severity at baseline p (between-group
comparison)
Mild (n = 61) Moderate(n = 150) Severe (n = 158)
AHI, /h
Baseline 11.1 ± 2.8 22.5 ± 4.4 43.3 ± 12.3
Three months 4.0 ± 3.7* 7.1 ± 6.1* 17.9 ± 17.2*
Difference −7.0 ± 4.0 −15.1 ± 6.7 −25.0 ± 16.4 <0.0001
AI, /h
Baseline 4.4 ± 3.5 7.7 ± 6.4 20.7 ± 15.1
Three months 1.0 ± 1.6* 2.0 ± 3.5* 7.9 ± 13.3*
Difference −3.3 ± 3.5 −5.6 ± 5.9 −13.5 ± 15.4 <0.0001
HI, /h
Baseline 6.8 ± 3.4 14.8 ± 6.5 22.5 ± 11.5
Three months 2.9 ± 2.8* 5.1 ± 4.2* 10.1 ± 8.9*
Difference −3.8 ± 3.6 −9.6 ± 7.4 −11.4 ± 12.6 <0.0001
Supine AHI, /h
Baseline 20.2 ± 13.5 32.1 ± 17.5 49.4 ± 23.1
Three months 5.5 ± 5.7* 9.7 ± 10.7* 20.6 ± 23.4*
Difference −14.9 ± 12.5 −20.9 ± 18.3 −26.9 ± 29.0 0.011
Mean SpO2, %
Baseline 94.6 ± 1.7 93.9 ± 1.8 93.1 ± 2.1
Three months 94.6 ± 1.5 94.0 ± 1.8 93.5 ± 2.0
Difference −0.1 ± 1.6 0.1 ± 1.5 0.2 ± 2.1 NS
cAI, /h
Baseline 0.2 ± 0.4 0.4 ± 0.8 0.8 ± 1.6
Three months 0.2 ± 0.3 0.3 ± 1.1# 0.8 ± 2.6
Difference −0.04 ± 0.36 −0.03 ± 1.05 0.04 ± 2.9 NS
Nadir SpO2, %
Baseline 84.6 ± 6.0 82.3 ± 6.7 80.0 ± 8.6
Three months 86.9 ± 8.0* 84.9 ± 9.1* 83.5 ± 8.0**
Difference 2.1 ± 10.4 2.8 ± 10.0 3.5 ± 7.9 NS
TSpO2 <90%, min (median (Q1, Q3)) NS
Baseline 2 (0, 7) 6 (1, 17) 12.5 (2, 42.5)
Three months 0 (0, 1)*** 0.9 (0, 8)* 4.0 (0, 23)***
Difference −1 (−22.8, 1.5) −2 (−12, 0) −1 (−4, 0)
ODI, /h
Baseline 10.9 ± 8.3 16.3 ± 13.1 30.9 ± 21.1
Three months 4.4 ± 6.8* 8.2 ± 9.7* 14.2 ± 16.1*
Difference −5.9 ± 10.7 −8.6 ± 14.3 −15.4 ± 23.2 0.003
Values are mean ± standard deviation, unless stated otherwise.
AHI, apnoea–hypopnoea index; AI, apnoea index; cAI, central apnoea index; HI, hypopnoea index; mild, AHI 5/h to <15/h; moderate, AHI ≥15/h to <30/h; NS, not signiﬁ-
cant; ODI, oxygen desaturation index; OSAHS, obstructive sleep apnoea–hypopnoea syndrome; severe, AHI ≥30/h; TSpO2 <90%, time with oxygen saturation <90%; SpO2,
oxygen saturation; Success, ≥ 50% decrease in AHI.
* p < 0.0001 vs baseline.
** p < 0.001 vs baseline.
*** p < 0.01 vs baseline.
# p < 0.05 vs baseline.
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this study were not excluded for criteria that were previously iden-
tiﬁed to inﬂuence MRD effectiveness (eg, AHI, BMI, sex, age) in other
studies. The present results suggest that MRDs may be indicated
for themajority of patients who are noncompliant with CPAP therapy.
Moreover, 25% of participants received additional titration after the
ﬁrst 3-month PG/PSG control to achieve optimal eﬃcacy, showing
that objective measurement of AHI is essential for controlling MRD
therapy and that proper individualised titration is probably as im-
portant as patient selection.
Improvements in snoring in this study were not only subjec-
tively assessed but also objectively determined using PSG/PG, which
conﬁrmed that the MRD-related improvements reported by
patients and partners are consistent with existing data [28]. Re-
ported reductions in daytime sleepiness and the incidence of
excessive sleepiness were also of a similar magnitude to previ-
ously reported changes [28–31] and similar to those achieved with
CPAP [29]. Furthermore, this study documented signiﬁcantly im-
proved QOL afterMRD therapy using the Quebec Sleep Questionnaire.
Not many previous studies have explored QOL after MRD treat-
ment [30,32–34].
Subjectively assessed MRD compliance in this study was
excellent (95.8%). Previous reports of self-assessed compliance with
MRD therapy have ranged from 76 to 95% [29]. Recent data suggest
that there is good similarity between subjective and objective
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Fig. 4. Effects of mandibular repositioning device therapy on snoring: (A) based on polysomnology data or (B) patient self-report (*p < 0.0001 vs baseline).
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long-term compliance rates with MRD therapy [35,36]. Thus, even
though CPAP remains the treatment of choice in severe OSA, better
long-term compliance with MRD therapy could minimise actual dif-
ferences between the effectiveness of MRD and CPAP in clinical
practice [16,35].
MRD therapy is currently recommended for the treatment of pa-
tients with mild or moderate OSAHS (level A recommendation)
[15,16,29,37]. A large subgroup of participants (42.8%) in the current
study had severe OSAHS (AHI >30/h) and MRD was able to signiﬁ-
cantly reduce AHI, despite high mean baseline AHI values (43 ± 12/
h). Thus, while an MRD might be less effective for resolving severe
OSAHS compared with mild/moderate disease, a signiﬁcant number
of patients with severe OSAHS have been effectively treated with
an MRD [16,38].
The results of this ‘real-life’ study show that a custom-made
Narval™ MRD is effective and well tolerated in OSAHS patients who
refuse or do not tolerate CPAP. Signiﬁcant improvements were docu-
mented in AHI, SpO2, clinical symptoms and QOL in mild-to-
moderate and severe OSAHS. The Narval™ MRD device is custom-
made with ﬂexible biocompatible polyamide; such soft acrylic
materials have been shown to be better tolerated and to have better
eﬃciency than thermoplastic monobloc or hard acrylic MRDs [23,29].
Moreover, the traction-based triangle and connector articulations
enable mandibular advancement in parallel to the occlusion plane.
This vector of advancement reduces stress on muscles and TMJ
contact force [39], and may be a possible explanation for the good
tolerance of MRD in the present cohort. MRD therapy was well tol-
erated in this study and most participants expressed a desire to
continue using the MRD.
Treatment success (76%) and complete response (64%) rates with
Narval™ MRD in this study were at the upper end of the range re-
ported in previous studies of MRD devices in OSAHS. Data from
randomised, controlled trials have shownmean decreases in the fre-
quency of respiratory disturbances of 14–80% with MRD therapy
[28,29] and complete response rates of 50–70% [28,32]. In parallel
with AHI improvements,MRD therapy signiﬁcantly increasedminimal
SpO2, signiﬁcantly decreased time spent with SpO2 <90% and the ODI
to a similar extent, as previously reported [29,40].
In the present study, use of a CAD/CAMMRD devicewas also a sig-
niﬁcant independent predictor of treatment success, suggesting that
the type of MRDmay have an important inﬂuence on the outcome of
therapy.Waist circumferencewas found to be an independent predic-
tor ofMRDeﬃcacy, and amuch stronger predictor than BMI.Moreover,
in univariate analysis, success rate and complete response in obese pa-
tientswere 58.1% and 44.3%, respectively. Consistentwith existing data,
other results have suggested thatMRDeﬃcacy is not affected by supine-
dependent OSAHS [41]. Greater overbite was a signiﬁcant predictor
of treatment success, which may predispose patients with mandibu-
lar retrognathia, especially thosewith class II division 2malocclusions,
to a high success rate, in accordance with previous data on MRDs.
The associations that were found between MRD treatment outcome
and both functional and morphological factors should be taken
into account in therapeutic decision-making.
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Table 3
Side effects reported during mandibular repositioning device therapy.
Side effects during MRD therapy, n (%)
Minor,
n (%)
Severe,
n (%)
Requiring
treatment
withdrawal
TMJ pain 49 (13.3) 13 (3.5) 2 (0.5)
Dental pain 46 (12.5) 8 (2.2) 8 (2.2)
Occlusion change 50 (13.6) 1 (0.3) 2 (0.5)
Gingival bleeding 26 (7.1) 3 (0.8) 3 (0.8)
Periodontal pain 23 (6.3) 6 (1.6) 3 (0.8)
Dental mobility 19 (5.1) 1 (0.3) 1 (0.3)
Mouth dryness 18 (4.9) 0 0
Hypersalivation 14 (3.8) 1 (0.3) 1 (0.3)
Gingival pain 11 (3.0) 3 (0.8) 1 (0.3)
Jaw pain 10 (2.8) 2 (0.5) 2 (0.5)
Teeth clenching 10 (2.7) 0 1 (0.3)
TMJ disorders 7 (1.9) 3 (0.8) 0
Gingivitis 5 (1.3) 5 (1.4) 2 (0.5)
Broken MRD 5 (1.3) 4 (1.1) 4 (1.1)
Dental fracture 2 (0.5) 4 (1.1) 0
Mild tooth migration 6 (1.6) 0 0
Jaw stiff 6 (1.6) 0 0
Local inﬂammatory reaction 1 (0.3) 1 (0.3) 1 (0.3)
Prosthesis loosening 2 (0.5) 0 0
MRD, mandibular repositioning device; TMJ, temporomandibular joint.
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As mentioned brieﬂy above, outcomes in the present study ap-
peared to be better for participants treated with a CAD/CAMMRD.
In most studies, greater protrusion was associated with better im-
provement in AHI, nocturnal oxygen desaturations, and pharyngeal
collapsibility [23,32,42,43]. The same gradual titration procedures
were followed with the two MRD devices, but results with the non-
CAD/CAM device were comparable to recent published data from
a study with no systematic MRD titration [26]. The present results
suggest that the better eﬃcacy of the CAD/CAM device may be due
to its speciﬁc design and/or different manufacturing process com-
pared with the non-CAD/CAM device. There are several potential
explanations for this, including: differences in material plasticity,
shape and thickness of splints, and the degree of vertical dimen-
sion of occlusion provided. It has been shown that vertical opening
may have a signiﬁcant effect on pharyngeal collapse in some pa-
tients [44] and may, therefore, reduce MRD eﬃcacy. The
manufacturing process for the CAD/CAM NarvalTM device allows ac-
curate adjustment of the vertical opening compared to the non-
CAD/CAM device. This may be one mechanism that contributed to
the higher eﬃcacy seen with CAD/CAM device in this study. What
is important is that use of a titratable and adjustable MRD device
is essential, and that effective and individualised mandibular titra-
tion plays a key role in therapy success [16,30,45].
Although MRD therapy had no signiﬁcant effects on blood pres-
sure in the overall study population, there was an indication that
greater reductions in blood pressure from baseline were observed
in those with pre-existing hypertension. This is something that war-
rants further investigation in future clinical trials.
The present study had some limitations. There was no control
group, but the primary aim was to assess long-term MRD eﬃcacy
and tolerability in a large real-life cohort of severe and/or symp-
tomatic OSAHS patients who were noncompliant with CPAP and
requiredmandatory treatment. Compliance data were based on sub-
jective reports, but because previous data have shown good
concordance between subjective and objective compliance assess-
ments [34], this is unlikely to have inﬂuenced the ﬁndings.
The results of this study, which show good eﬃcacy, tolerability
and adherence with MRD therapy, support the use of this
intervention in OSAHS patients who refuse or do not tolerate CPAP,
including those with severe disease. Long-term follow-up is
continuing and further assessments, including PSG/PG, will be per-
formed after two and ﬁve years, which will allow additional data
Table 4
Univariate predictors of treatment success and complete response for mandibular repositioning device therapy.
Variable Yes No OR (95% CI) p
Treatment success (≥50% decrease in AHI)
Type of device, % participants
Non-CAD/CAM 60.7 39.3 Reference
CAD/CAM 79.1 20.9 2.45 (1.34–4.49) 0.0031
Sex: M/F, % participants 73.6/83.3 26.4/16.7 1.79 (0.96–3.33) 0.063
Neck circumference, cm 39.2 ± 3.6 40.8 ± 3.7 0.89 (0.82–0.96) 0.0022
Waist circumference, cm 95.7 ± 11.9 101.9 ± 12.7 0.96 (0.94–0.98) 0.0001
BMI, % participants
Normal 86.0 14.0 Reference
Overweight 78.5 21.5 0.60 (0.31–1.16) NS
Obese 58.1 41.9 0.23 (0.11–0.46) <0.0001
Malocclusion dental class, % participants
I 74.8 25.2 Reference
II 85.4 14.6 1.98 (1.04–3.76) 0.067
III 66.7 33.3 0.68 (0.22–2.06) NS
Dental overbite, mm 3.0 ± 2.0 2.2 ± 1.9 1.27 (1.09–1.49) 0.0004
Maximum jaw protrusion, mm 9.1 ± 2.5 8.2 ± 2.1 1.20 (1.07–1.34) 0.0019
Dental overjet, mm 3.1 ± 1.8 2.3 ± 1.8 1.31 (1.11–1.55) 0.0013
Mandibular advancement, % 85.6 ± 26.0 91.1 ± 26.4 0.990 (0.980–0.999) 0.009
Baseline AHI, /h 28.3 ± 13.9 33.8 ± 18.3 0.98 (0.96–0.99) 0.028
Baseline AI, /h 11.6 ± 12.3 17.6 ± 14.3 0.97 (0.95–0.99) 0.0001
Supine AHI, /h 35.6 ± 21.2 41.9 ± 25.6 0.99 (0.98–1.00) 0.098
Mouth breathing: yes/no, % participants 73.1/82.3 26.9/17.7 1.72 (0.95–3.09) 0.070
Complete response (AHI <10/h)
Type of device, % participants
Non-CAD/CAM 49.1 50.9 Reference
CAD/CAM 67.5 32.5 2.16 (1.20–3.91) 0.010
Sex: M/F, % participants 60.5/76.5 39.5/23.5 2.12 (1.21–3.73) 0.0078
Neck circumference, cm 38.9 ± 3.6 40.9 ± 3.5 0.84 (0.78–0.91) <0.0001
Waist circumference, cm 94.5 ± 12.1 101.5 ± 11.3 0.95 (0.93–0.97) <0.0001
BMI, % participants
Normal 77.9 22.1 Reference
Overweight 64.7 35.3 0.52 (0.30–0.92) <0.0001
Obese 44.3 55.7 0.23 (0.12–0.44) <0.0001
Dental overbite, mm 3.0 ± 2.0 2.5 ± 2.0 1.16 (1.02–1.31) 0.0066
Maximum jaw protrusion, mm 9.2 ± 2.4 8.6 ± 2.4 1.12 (1.02–1.24) 0.028
Dental overjet, mm 3.1 ± 1.8 2.5 ± 1.7 1.23 (1.07–1.41) 0.0047
Mandibular advancement, % 83.0 ± 25.4 88.3 ± 26.4 0.99 (0.98–1.00) 0.040
Baseline AHI, /h 23.7 ± 11.4 39.1 ± 15.8 0.92 (0.90–0.94) <0.0001
Baseline AI, /h 8.9 ± 9.4 20.5 ± 15.7 0.92 (0.90–0.95) <0.0001
Baseline HI, /h 14.9 ± 8.9 18.6 ± 10.2 0.96 (0.94–0.98) 0.0012
Supine AHI, /h 31.5 ± 18.3 46.9 ± 25.2 0.97 (0.96–0.98) <0.0001
ESS score, % participants
≤10 58.3 41.7 Reference
>10 69.0 31.0 1.59 (0.99–2.55) 0.054
Mouth breathing: yes/no, % participants 61.4/73.0 38.6/27.0 1.70 (1.01–2.86) 0.044
AHI, apnoea–hypopnoea index; BMI, body mass index; CAD, computer-aided design; CAM, computer-aided manufacturing; CI, conﬁdence interval; ESS, Epworth Sleepiness
Scale; NS, not signiﬁcant; OR, odds ratio.
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analysis and more precise determination of factors predicting the
success of therapy.
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